Cardiovascular co-medication among users of antiobesity drugs: a population-based study.
OBJECTIVE
The purpose of this study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) used cardiovascular and antidiabetic drugs. An additional aim was to investigate whether such co-medication differed according to gender, age and amount of antiobesity drugs used.


METHODS
Data were retrieved from the Norwegian Prescription Database (NorPD). All patients who had an antiobesity drug (ATC code A08A) dispensed from a Norwegian pharmacy between January 2004 and December 2007 were included in the study.


RESULTS
During the 4-year study period 83,717 patients had antiobesity drugs dispensed. One in three patients using antiobesity drugs had at least on one occasion used a cardiovascular and/or an antidiabetic drug concomitantly. A significantly higher percentage of men used antihypertensives (40.4 vs. 27.2%, P < 0.0005), lipid modifying agents (24.4 vs. 11.9%, P < 0.0005) and drugs used in diabetes (12.7 vs. 6.4%, P < 0.0005) concomitantly with antiobesity drugs when compared to women. The percentage of patients who had concomitant drug use increased markedly with age. One in four patients had antiobesity drugs dispensed only once during the period 2004-2007.


CONCLUSIONS
Use of cardiovascular and antidiabetic drugs among patients using antiobesity drugs was extensive, especially among men and elderly patients. Overall, there was a high degree of polypharmacy among users of antiobesity drugs. Also, many patients dispensed antiobesity drugs in amounts that indicated use less than the recommended daily dose, and many dispensed antiobesity drugs only once. When prescribing antiobesity drugs to patients the potential benefits of antiobesity drugs should be considered in relation to the patients other chronic diseases and to the total complexity of the patients drug regimen.
Amundsen
Merethe Omdal
MO
Department of Pharmacy, School of Pharmacy, University of Oslo, P.O. Box 1065, 0316, Blindern, Norway.
Engdahl
Bo
B
Berg
Christian
C
Nordeng
Hedvig
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007223:Infant; D008297:Male; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D019338:Polypharmacy; D011159:Population Surveillance / Q000379:methods; D055815:Young Adult
D019440:Anti-Obesity Agents; D002317:Cardiovascular Agents; D007004:Hypoglycemic Agents
Diabetes Care. 2003 May;26(5):1408-12
12716797
Fundam Clin Pharmacol. 2010 Feb;24(1):9-17
19817871
Am J Health Syst Pharm. 2009 Aug 15;66(16):1471-7
19667004
Int J Clin Pharmacol Ther. 2009 Feb;47(2):104-10
19203566
Tidsskr Nor Laegeforen. 2007 Jan 4;127(1):34-7
17205087
Pharmacoepidemiol Drug Saf. 2009 Jul;18(7):631-8
19415767
Br J Gen Pract. 2005 Oct;55(519):743-9
16212848
BMC Fam Pract. 2006 Jul 07;7:43
16827937
Int J Obes Relat Metab Disord. 2003 Nov;27(11):1434-5
14574358
Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):405-11
16981229
Br J Gen Pract. 2008 Aug;58(553):548-54
18682018
J Gen Intern Med. 2007 Jun;22(6):805-10
17406952
BMJ. 2006 Sep 23;333(7569):640-2
16990325
BMJ. 2007 Dec 8;335(7631):1194-9
18006966